Related Experiment Videos
Efficacy of felbamate in therapy for partial epilepsy in children
L Carmant1, G L Holmes, S Sawyer
1Department of Neurology, Children's Hospital, Boston, MA 02115.
Insights
Felbamate effectively reduced seizure frequency by 53% in children with refractory partial epilepsy. Older children showed better responses, though younger children exhibited increased drug clearance, requiring dosage adjustments.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Refractory partial epilepsy in children presents significant treatment challenges.
- Identifying effective and well-tolerated antiepileptic drugs is crucial for this population.
Purpose of the Study:
- To evaluate the efficacy and tolerability of felbamate as an add-on therapy for pediatric refractory partial seizures.
- To explore the relationship between patient age, felbamate pharmacokinetics, and treatment response.
Main Methods:
- Open-label study involving 30 children (2-17 years) with refractory partial seizures.
- Felbamate was administered as an add-on to existing antiepileptic drugs, with dose titration up to 45 mg/kg.
- Seizure frequency, adverse events, and drug concentrations were monitored.
Main Results:
- A 53% decrease in seizure frequency was observed during felbamate therapy compared to baseline.
- 50% of patients experienced over a 50% reduction in seizure frequency.
- Patients older than 10 years were more likely to respond favorably; age correlated with higher felbamate levels and lower clearance.
- Transient weight loss, anorexia, and insomnia were the most common adverse effects, generally well-tolerated.
Conclusions:
- Felbamate demonstrates significant efficacy and tolerability as a treatment option for refractory partial epilepsy in children.
- Age-dependent pharmacokinetic differences, particularly increased clearance in younger children, should guide therapeutic dosing strategies.
- Further research may be warranted to optimize felbamate use in specific pediatric age groups.
Abstract:
Thirty children (2 to 17 years of age) with refractory partial seizures received open-label felbamate as an add-on medication to their background antiepileptic drugs. The dose was increased up to a maximum of 45 mg/kg. Compared with baseline seizure activity, there was a 53% decrease in seizure frequency during felbamate therapy; 50% of the patients had more than a 50% decrease in seizure frequency. Patients older than 10 years of age were more likely to have a favorable response. Age correlated positively with felbamate concentrations and negatively with apparent felbamate clearance. Transient weight loss occurred in 57% of the patients; the weight loss was maximal after 12 weeks of initiation of felbamate, and subsided after the twentieth week of treatment. Anorexia and insomnia were reported in 20% and 16% of the patients, respectively. Adverse effects were generally tolerable; felbamate therapy was discontinued because of side effects in only one patient, because of a rash. We conclude that felbamate can be a useful and well-tolerated medication in the treatment of refractory partial epilepsy in children. However, increased apparent clearance of this drug in younger children should be considered in treatment of this age group.